PHP81 UNITED STATES PHD PROGRAMS IN PHARMACOECONOMICS AND OUTCOMES RESEARCH  by Slejko, JF et al.
A96 Abstracts
the following outcomes after controlling for individuals’ observed and unobserved 
characteristics together with their CMS risk scores: 1) Adjusted MLR spikes up at the 
same time as the share of enrollees who die also spikes upward; (2) Adjusted expenses 
paid by the plan on behalf of enrollees who died while enrolled are much higher than 
the CMS payments to the plan for the same enrollees in the month of death and in 
the 4 to 6 months prior to death; and 3) We found that death rates in each calendar 
month explain about 30 to 40% of adjusted MLR. CONCLUSIONS: The results show 
that Medicare Part A utilization and expenditures have a limited role in the increasing 
trend of adjusted MLR for beneﬁciaries who survive through the enrollment period. 
However, we ﬁnd a positive, stronger and statistically signiﬁcant correlation between 
inpatient visits and the expenses for enrollees who died while enrolled. The correlation 
remains signiﬁcant up to 24 months prior to the death of an enrollee.
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OBJECTIVES: In Canada, the CDR conducts health technology assessments and 
provides funding recommendations to participating jurisdictions. These recommenda-
tions are publically available but little research has been conducted to understand 
the rationale behind these decisions. Furthermore, the acceptable ICER for the CDR 
is not published but is generally perceived to be $50,000/QALY. This study was 
conducted to analyze published CDR recommendations to determine if speciﬁc factors 
inﬂuence decision-making. METHODS: For this abstract, four variables were con-
sidered for 143 recommendations (December 2003 to October 2009). These variables 
include manufacturer-submitted ICER, ﬁrst-in-class status, therapeutic categories, 
and request for reconsiderations. RESULTS: Thirty-seven of 143 CDR recommenda-
tions reported ICER values and were analyzed. The average ICER was $47,900 ± 
29,100/QALY (N = 20) for “List” recommendations and $91,400 ± 52,300/QALY 
(N = 17) for “Do not list” recommendations (p < 0.05). A trend towards statistical 
signiﬁcance for an effect of ﬁrst-in-class on receiving negative recommendation was 
observed (Fisher’s exact test, p = 0.0873). There appeared to be an overall effect 
of therapeutic category on recommendation (χ2: 36.213, df: 11, p < 0.0001). An 
effect of requests for reconsideration on recommendation outcome was also observed 
(Fisher’s exact test, p < 0.0001). CONCLUSIONS: From the pharmacoeconomics 
perspective, the average ICER of $47,900/QALY is in alignment with the perceived 
limit, although majority of reviews did not have a reported ICER. Nonetheless, 
considerable variation in the ICER indicated additional factors inﬂuence CDR 
decision-making. Being ﬁrst-in-class had small but non-signiﬁcant inﬂuence on CDR 
recommendation. Therapeutic category had signiﬁcant inﬂuence on recommendations 
although the sample size was small and further investigation is needed to determine 
the cause. Finally, requests for reconsideration did little to inﬂuence the initial CDR 
recommendation. The overall ﬁndings suggested that while the ICER may be an 
important input into the decision-making process, careful examination of other 
factors will be needed to further understand the relative inﬂuence of the ICER on 
ﬁnal CDR recommendations.
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OBJECTIVES: In order to meet the cost-effectiveness requirements of the National 
Institute for Health and Clinical Excellence (NICE), manufacturers are increasingly 
utilizing innovative pricing agreements (IPAs). This research aims to identify all such 
agreements from published NICE appraisals and to provide recommendations to 
pharmaceutical companies on their utility. METHODS: All completed NICE technol-
ogy appraisals published from 2006 to 2009 were reviewed and any submission in 
which the guidance included an IPA was identiﬁed. An IPA was deﬁned as the manu-
facturer providing a pre-deﬁned reduction of the overall cost of treatment based on 
risk sharing or rebate schemes. RESULTS: The inclusion of IPAs in NICE guidance 
is increasing over time. Of 18 appraisals published in 2006 none included an IPA. 
There was an IPA element in 5% (1/21) appraisals in 2007, increasing to 7% of 
appraisals (2/27) in 2008, and 22% (4/18) in 2009. Of the 7 IPAs identiﬁed from 
2006 to 2009, 5 were for oncology products, the others being for psoriasis and age-
related macular generation. The form of the IPAs could be broadly categorized into 
1) a rebate across a speciﬁc patient population (N = 3); 2) drug provided free for 
patients remaining on treatment beyond a speciﬁc point (N = 2); 3) provision of free 
ﬁrst cycle of treatment (N = 1) and 4) cost matched to existing treatment (N = 1). 
IPAs were included through initial proposals to the Department of Health by the 
manufacturer (N = 3), as part of the revised manufacturer’s model following the initial 
review (N = 3) and through proposals by the NICE committee (N = 1). CONCLU-
SIONS: Pharmaceutical companies are increasingly using innovative price agreements 
in their NICE submissions. Such agreements are mutually beneﬁcial and acceptable to 
both parties and provide an opportunity for companies to demonstrate their conﬁ-
dence in the value claims of speciﬁc therapies.
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OBJECTIVES: The study was conducted to describe the characteristics and quality of 
health economic (including pharmacoeconomics) evaluation research studies related 
to Nigeria. METHODS: A literature review was conducted to identify health economic 
evaluation articles. Main databases (e.g., PUBMED, MEDLINE) were used to search 
for economic analyses. The study included only original economic evaluations that 
pertained to Nigeria, addressed a health-related topic (e.g., pharmacy) and were 
complete peer-reviewed publications in the English language. Two reviewers indepen-
dently evaluated and scored each article in the ﬁnal sample using a data collection 
form. RESULTS: The 44 identiﬁed articles were published in 34 different journals 
mostly based outside of Nigeria between 1988 and 2009. On average, each article 
was written by four authors. Most (98%) ﬁrst authors had medical/clinical training 
and resided in Nigeria (75%) at the time of publication of the study. Based on a 1 to 
10 scale, with 10 indicating the highest quality, the mean quality score for all studies 
was 7.29 (SD = 1.21) and 59 percent of the articles were of fair quality (score 5–7). 
The quality of articles was statistically signiﬁcantly related (p < 0.05) to the country 
of residence of primary author (non-Nigeria = higher), the country of journal 
(non-Nigeria = higher), primary objective of the study (economic evaluation as the 
objective = higher), and type of economic analysis conducted (full economic evalua-
tions = higher). The quality of the articles was not signiﬁcantly related to the sample 
size, type of data (primary vs secondary), number of authors, type of publication, year 
of publication, study perspective and primary health intervention (p > 0.05). CON-
CLUSIONS: The conduct of health economics (including pharmacoeconomics) evalu-
ation research in Nigeria is limited and about two-thirds of published articles were of 
fair quality. More and better quality health economics research in Nigeria is 
warranted.
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OBJECTIVES: This study aimed to summarize the current status and desired compo-
nents of pharmacoeconomics and outcomes research PhD programs. METHODS: 
Using the educational directory on the ISPOR website, 32 PhD programs were identi-
ﬁed and contacted. Programs’ participation in an online survey was requested if their 
program focused on pharmacoeconomics, outcomes research or related ﬁelds. The 23 
question survey asked for speciﬁc information about their program, faculty, staff and 
students as well as their insight on factors important to such training. RESULTS: Of 
the 32 programs contacted, 14 (44%) responded, with two stating that their program 
did not ﬁt the inclusion criteria. Of the ﬁve programs offering degrees in pharmaceuti-
cal outcomes or economics speciﬁcally, 1994 was the earliest year of establishment 
and 2001 the most recent. The remaining programs provided such training within 
broader and more established programs. On average, programs had seven full-time 
faculty, four staff and 15 current PhD students. When asked about the ideal number 
for a program’s success, 8 full-time faculty and 17 students were desired. Historically, 
51% of students had a previous Master’s degree, 36% had a professional degree and 
about 16% had a Bachelor’s degree only. The mean time for completion of coursework 
was 2.7 years and 4.9 years to graduation. After graduation, 32% of students take a 
job in academia, 41% take a job in industry and 10% take a post-doctoral position. 
When asked about factors contributing to a program’s success, reputation of faculty’s 
research was thought to be most important. For students entering a PhD program in 
this ﬁeld, faculty’s mentoring experience and reputation was considered most impor-
tant. CONCLUSIONS: Programs offering speciﬁc training in this ﬁeld have only been 
in existence about 15 years. Programs appear to be growing, as desired number of 
faculty and students are higher than average numbers existing presently.
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OBJECTIVES: The US Food and Drug Administration (FDA) proposed labeling 
changes to be implemented by April 29, 2010 that would improve inappropriate 
and excessive use of over-the-counter (OTC) internal analgesic, antipyretic and anti-
rheumatic drugs (IAAA). This study examined the attitude and knowledge of phar-
macists about these labeling changes as pharmacists regularly advise on such products 
to consumers. METHODS: A prospective, cross-sectional study was conducted by 
surveying pharmacists working in a 15 mile radius of the Texas Medical Center. 
The survey instrument consisted of a 25 item questionnaire. Cronbach’s alpha (0.89) 
was used to assess the internal consistency of the instrument. Two-sided studentized 
t-test (μ = 3, α = 0.05) and descriptive statistics were used to analyze pharmacist’s 
attitude and awareness respectively for each individual parameter pertaining to the 
labeling changes. RESULTS: A total of 51 (out of 70) community pharmacist par-
